Dr. Hope S. Rugo on the SOPHIA Trial in HER2+ Breast Cancer
June 12, 2019
Cancer Network spoke with Hope S. Rugo, MD, of the University of California, San Francisco, about the results of the phase III SOPHIA trial in HER2-positive breast cancer.
Hope S. Rugo, MD
Neoadjuvant Therapy for HER2-Positive Early-Stage Breast Cancer: The Future Is Almost Here
January 18, 2012
It may not be appropriate, nor always considered standard, to recommend neoadjuvant chemotherapy for all patients for whom adjuvant therapy was recommended before surgery. Indeed, tumor size and nodal status play a role, as do hormone receptors, in determining the appropriate extent of adjuvant therapy.
